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Outcomes in ST Elevation Myocardial Infarction; a comparison of a
tertiary care center in Pakistan with European centers
Sadia Arshad, Sajid Dhakam, Safia Awan
Department of Medicine, Aga Khan University Hospital, Karachi.

Abstract
Objectives: To evaluate the clinical characteristics and in hospital outcome data of patients presenting to the
Aga Khan University Hospital with ST elevation Myocardial Infarction (STEMI) and its comparison with data from
patients enrolled in the European Heart registry for the same duration.
Methods: Data on 296 patients with STEMI was prospectively collected from 1st January 2010, till 31st
December 2010 from the cardiology section at the Aga Khan University Hospital. European data was collected
on 7485 patients retrieved from the Eurobservational Research programme Acute Coronary Syndrome Registry
2010 for the same duration.
Results: A total of 296 patients were enrolled from AKUH and 7485 from European centers for the year 2010.
Majority of patients in both groups were male. Pakistani patients were more likely to be younger and diabetic
(p<0.05) with higher frequency of prior myocardial infarction and angina (p<0.05). They were less likely to be
smokers and previously diagnosed as dyslipidemic. Most patients presented to hospital with chest pain, median
time between symptom onset and hospital arrival was 3.8 (2.0-8.5) hours. One third of European patients
received a thrombolytic agent compared with less than 5% of AKU/Pakistani patients. Almost 90% of
AKU/Pakistani patients underwent primary percutaneous intervention. Approximately 5.8% of our patients were
not candidates for any reperfusion therapy vs. 4.8% of European patients.
On coronary angiogram, the majority of patients had single or two vessel Coronary Artery Disease. We had a higher
frequency of high risk lesions, 97.86 vs. 84.14 %( p=0.002).Our patients had more drug eluting stents 42.5% vs.
25.9 %( p=0.01) implanted, due to more diabetics and smaller vessel size. We also had a similar proportion of
patients undergoing coronary artery bypass graft. Frequency of complications was similar for both cohorts. Median
hospital stay in our patients was shorter, survival at hospital discharge being similar between both groups (P=0.42)
Conclusions: The patients presenting to Aga Khan University Hospital with STEMI were younger and more
likely to be diabetic. They had a higher frequency of prior Myocardial Infarction and angina. They underwent
revascularization with primary percutaneous intervention more often and usually for more complex lesions
requiring greater use of drug eluting stents. Survival at discharge was similar compared to European Centers.
Keywords: ST elevation MI, Primary angioplasty, Thrombolysis (JPMA 61: 1215; 2011).

Introduction
An atherosclerotic plaque with a large lipid core, thin
fibrous cap and evidence of inflammation may result in
fissuring of the plaque. Plaque rupture and resultant platelet
activation and thrombosis leads to epicardial artery occlusion,
accounting for the majority of ST segment elevation
myocardial infarction (STEMI). Distal embolisation of
thrombus compounds the problem. In patients without
obstructive coronary artery disease (CAD) the reasons for
STEMI are coronary artery dissection, embolisation and
vasospasm. This may occur in 5-10% of cases.1-4 Restoration
of coronary blood flow to the infarct related artery is the
guiding principle of treatment of STEMI. Rapid availability
of reperfusion therapy, whether pharmacological (fibrinolytic
therapy) or catheter based intervention, primary percutaneous
intervention (PCI) limits infarct size and improves survival.5
The Global Registry of Acute Coronary Events (GRACE)
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suggested that up to 40% of patients with STEMI do not
receive reperfusion therapy.6 When facilities for primary PCI
are available; it has been proven superior to fibrinolysis in
respect to improved survival, recurrent myocardial infarction
and stroke.7-13
Administration of thrombolytic therapy within the first
hour is associated with greatest benefit with regards to
mortality. Collective data from several large trials revealed a
22% short term mortality reduction when patients underwent
PCI as compared with fibrinolysis.14 White and colleagues
suggested that increasing the numbers of patients treated with
reperfusion therapy would save an estimated 270 lives per 10
000 STEMI patients. Reducing time to fibrinolysis or
changing to a PCI strategy from lysis would save an estimated
154 lives / 10 000 STEMI patients.1 STEMI is the component
of the acute coronary syndrome with highest in hospital
mortality. As physicians in the developing world, with limited
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resources our challenge is to evaluate our own population
presenting with this illness .We need to compare their clinical
characteristics, management and outcomes with those from
other communities. This is how we will assess our own
practices and identify areas where improvement is necessary.
The objective was to evaluate the clinical
characteristics and in hospital outcomes of patients presenting
to the Aga Khan University Hospital with ST elevation MI and
compare them with data from patients enrolled in the
European Heart registry33 for the same time period.

Patients and Methods
This is a cross sectional observational study with data
on 296 patients with STEMI prospectively collected from 1st
January 2010, till 31st December 2010 at the Aga Khan
University Hospital .All patients admitted to the coronary
care unit with the primary diagnosis of ST Elevation
Myocardial Infarction, either from emergency room or within
the hospital were enrolled after informed consent. The
inclusion criteria was adults presenting with STEMI to the
Aga Khan University hospital. STEMI was defined as
clinical presentation with chest pain > 20 minutes and ST
elevation of more than 1mm in at least 2 contiguous leads or
new onset left bundle branch block on 12 lead ECG. The
exclusion criteria was patients were excluded if they had
STEMI as a complication of PCI or CABG.
European data was retrieved from 7485 patients
enrolled with the Euro Observational Research programme
Acute Coronary Syndrome Registry 2010 during the same
period.33
SPSS© (version 19) was used for data analysis.
Results were reported as mean ± standard deviation for
quantitative variables and frequency (percentage) for

qualitative variables. Median and inter-quartile range was
calculated for non-symmetric variable like age. Student's t
test was used to compare means of quantitative variables
and Chi square (or Fisher's exact) test for categorical
variables. All P values were 2 sided and values <0.05 were
considered significant.

Results
Mean age of our patients was less than that of the
European patients. Majority of patients in both series were
male (p=0.003). The patient population presenting to Aga
Khan University Hospital with STEMI was younger and more
likely to be diabetic. They had a higher proportion of prior
myocardial infarction and angina (p<0.005).There was a
statistically insignificant trend towards a larger number of prior
interventions, both PCI and CABG. We had a lower proportion
of both current and former smokers as well as persons with
dyslipidaemia compared with the Europeans (Table-1).
Two thirds of patients in both groups were not on any
medical therapy prior to this hospitalization. Most patients
presented to hospital with chest pain (Table-2), fewer
presented with dyspnoea, syncope, arrhythmias and cardiac
arrest (or aborted sudden cardiac death).
Symptom onset to hospital arrival occurred in a
median 3.8 (2.0-8.5) hours in our patients compared with
3.0(1.7-6.5) hours in the European patients.
The majority of patients in both groups were
characterized as being in Killip class 1 on presentation,
since they had no evidence of heart failure or cardiogenic
shock on arrival.
About a third of European patients, but only around
5% of our patients received thrombolysis (Table-3). Our
patients had a higher proportion undergoing primary

Table-1: Baseline Data.
Risk factors
Age Median (IQR)*
Age >75 years %
Male
Female
Diabetes Mellitus
Hypertension
Dyslipidemia
Family History of premature CAD
Current smoker
Prior MI/angina
Prior history of CHF
Prior History of PCI
Prior History of CABG
Chronic Kidney disease
Prior use of ASA

European registry n=7485 (%)

AKUH n=296 (%)

P value

59.7(50.1-71.8)
1496 (19.6)
5887 (78.7)
1598 (12.3)
1759 (23.7)
3633 (49.1)
2538 (36.8)
1815 (25.6)
3268(44.3)
2185 (29.4)
336 (4.5)
514 (6.9)
108 (1.4)
212 (2.8)
1378 (25)

57.8 (50.1-66.6)
34( 11.5)
238 (80.4)
58 (19.6)
102 (34.4)
153 (51.7)
69 (21.7)
72 (24.3)
70 (23.6)
126 (42.6)
3(1)
29 (9.8)
10 (3.4)
7 (2.4)
74 (18.6)

P=0.88
p<0.005
P=0.003
p<0.001
p=0.38
P=0.013
p=0.62
p<0.001
p<0.001
P=0.17
P=0.44
P=0.31
P=0.65
P=0.30

IQR =interquartile range ,p value calculated by Mann Whitney U test. P<0.05-Significant.
CAD: Coronary Artery Disease. MI: Myocardial Infarction. CHF: Congestive Heart Failure. PCI: Primary Percutaneous Intervention. CABG: Coronary Artery Bypass Graft.
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percutaneous intervention (PCI) as the preferred reperfusion
strategy (88.4 vs. 52.3%).
Around 5.4 % (4.8% for Europeans) patients were
treated medically and did not receive reperfusion therapy,
mostly due to late arrival and completed infarcts.
On coronary angiogram, the majority of patients had
Table-2: Clinical presentation.
Presenting
complaints

European registry
n=7485 (%)

AKUH
n=296 (%)

P value

6870 (91.8)
187 (2.5 )
116 (1.6)
155(2.1)

262 (88.5)
14(4.7)
4(1.4)
3 (1)

0.04
0.01
0.73
0.19

Chest pain
Dyspnea
Syncope
Cardiac arrest

single or two vessel CAD (Figure).

Table-3: Reperfusion Strategy.
Reperfusion
strategy

European registry
n=7485 (%)

No reperfusion received
Thrombolytic
PCI strategy:
Primary
Facilitated
Rescue
CABG

AKUH
n=296 (%)

P value

360 (4.8)
2493 (33.3)

16(5.4)
14 (4.7)

p=0.63
p<0.005

3408 (52.3)
180(2.4)
546(7.3)
299 (4)

236 (88.4)
3(1.1)
1(0.4)
18(6)

p<0.005

P=0.08

Table-4: Left Ventricular function post STEMI.
Pre-discharge
LV function

European registry
n=7485 (%)

EF Preserved (>50%)
EF Mildly reduced (41-50%)
EF Moderately reduced (31-40%)
EF Severely reduced (<30%)

2957(40.6)
3378(25.4)
2077(16.1)
1047(7.8)

AKUH
n=296

P value

123(48.6)
65(25.7)
36(14.2
19(7.5)

0.28

EF: Ejection Fraction. LV function not assessed in 10% European patietns and 4%
Pakistani patients.

Table-5: Complications of Myocardial Infarction.
Complications

Congestive heart failure
Cardiogenic shock
Mitral regurgitation
Stroke
Major bleeding episode

European registry
n=7485 (%)

AKUH
n=296

P value

1257(16.8)
483(6.5)
87(1.2)
65(0.9)
95(1.3)

47(13.9)
3(1)
3(1)
1(0.3)
3(1)

0.57
0.12
1.0
1.0
1.0

European registry
n=7485 (%)

AKUH
n=296

P value

6970(93.1)
514(6.9)

272(91.9)
24(8.1)

0.42

Table-6: in hospital survival post STEMI.
Survival

Alive
Dead
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Figure: Number of coronary arteries involved in patients with STEMI.

About a fifth of patients in both groups had 3 vessel
CAD. Less than 1% percent patients in both groups had the
left main coronary artery as the culprit vessel.
Angiographically, our patients had a higher
proportion of high risk lesions 97.86 vs. 84.14 %(
p=0.002).Our patients had more drug eluting stents implanted
42.5% vs. 25.9% (p=0.01), due to more diabetics, smaller
vessel size and complex coronary anatomy. Procedural
success, defined as achievement of TIMI III flow in the
infarct related artery, was 98.1%. Rates of referral for CABG
were similar in both groups (8.9% vs. 6.08%).
The majority of patients in this study had preserved
left ventricular function assessed on echo prior to hospital
discharge (Table-4), reflecting timely management and
indicative of myocardial salvage in these patients. Despite
comparatively delayed presentation, only 21.7% of our
patients had an ejection fraction below 40%.
Clinically significant complications from myocardial
infarction were infrequent, with no statistically significant
difference in both groups (Table-5).A major bleeding episode
was defined as overt clinical bleeding with a drop in
haemoglobin of >0.5g/litre (or a drop in haematocrit by 15%).
Medical therapy received was similar in both groups,
with no significant differences in anti-platelets agents, beta
blockers, ACE inhibitors/ angiotension receptor blockers or
statins between both groups (p values NS for all)
Median hospital stay in our series was shorter, 4.0
(3.5-6.0) days as compared with 7.0 (5.0-10). Survival at
hospital discharge was also similar between both groups,
91.9% for the AKUH cohort vs. 93.1% (P =0.42) for
European patients.

Discussion
This study was done to evaluate the clinical profile of
J Pak Med Assoc

patients presenting with STEMI at a tertiary care center in
Pakistan. Our patients had a mean age of 58 similar to those
reported by other centers from the same part of the world,
which is consistently younger than patients presenting with
STEMI from the west.15-22
Numerous previous series have reported a male
preponderance in patients presenting with STEMI. Women
are known to have advanced age, increased co-morbidity and
increased short term mortality than men with STEMI. They
are also more likely to have symptoms labeled as "atypical"
.They are liable to receive less aggressive therapy and be
subject to delays, even if socio cultural and financial factors
are not considered.24,25 Female representation ranges from
18.2-35% in the literature, which is similar to our
experience.12,23
Diabetes was present in around a third of our patients,
which is similar to data from India, reported by Xavier et al.12
Jafary et al, from the same center found prevalence of
diabetes to be 41.7% and 32.1% in patients with STEMI
undergoing fibrinolysis and primary PCI respectively.26,27
Our population had prior history of a myocardial
infarction or angina in just less than half the patients which
was more than the Europeans (29.4%). In the registry from
India a previous MI was reported in 11.8% and a prior episode
of CHF was mentioned in less than 1% patients.12 Some of
these differences can be attributed to a referral center bias,
because of which patients with prior cardiac events ,co
morbidities and generally older age may be advised admission
to a multidisciplinary tertiary care center, even if they are
initially diagnosed to have STEMI at another local hospital.
The Pakistani cohort presented to a tertiary care center
in Karachi, that is JCIA certified and has a cardiac
catheterization laboratory with 24 hour coronary angiography
and PCI facilities.
Median presenting time since the onset of symptoms
was 3.8 hours ranging from 2 to 8.5 hours. This was longer
than the European patients, whose mean arrival time was 3
hours .In the Indian series 58.8% of patients presented later
than 4 hours after symptom onset.12 Jafary et al from the same
center had reported a mean 4.5 hour delay between symptoms
and hospital arrival for patients undergoing primary PCI and
90 minutes for those undergoing thrombolysis.26,27
Reasons for delay in presentation by the patient may
include lack of awareness as to the significance of symptoms,
lack of transport facilities, financial difficulties, and even
inaccurate initial diagnosis. In a society where majority of
patients do not have access to health insurance, there may be
a combination of reasons. Similar to our findings, Xavier et al
had reported government or insurance payment in 12.8% of
patients with STEMI in India.12
Vol. 61, No. 12, December 2011

About a fifth of our patients had a left ventricular
function less than 40% who may be candidates for an
implantable
cardioverter-defibrillator
or
cardiac
resynchronization therapy later on.
Pooled data from 23 randomized trials analyzed by
Keely et al suggested a mortality benefit with primary PCI.9
Timmer et al had reported that primary PCI was associated
with decreased mortality in both diabetic and non diabetic
patients, but with greater benefit in the diabetics.13
A significant majority of our patients underwent
Primary PCI compared to the European patients. The registry
data from India revealed that 58.5% of patients underwent
thrombolysis and 8% had undergone a primary PCI.
One of the main reasons why primary PCI was
considered to be a superior strategy by the attending
cardiologists at our center was the fact that the available
fibrinolytic agent was streptokinase, which is not fibrin
specific and has a lower rate of achieving TIMI III
flow,28,29 however it costs approximately $68 per patient.
Alteplase, a superior fibrinolytic, though available, costs
approximately similar to that of a primary PCI, $2408 vs.
$2500 for PCI (currently the US dollar stands at 85.9
Pakistani Rupees). Other reasons for preferring an
interventional strategy were that the 24 hour availability of
the cardiac catheterization laboratory guaranteed that the
estimated door to needle time would be minimized. Being
a multidisciplinary hospital, many of the patients
presenting to the AKUH were likely to be older and have
more co-morbidities. For the reasons mentioned above they
were more likely to have contraindications to thrombolysis
such as a prior history of intracranial pathology, (especially
stroke) recent surgery, trauma, malignancy and be advised
anticoagulation for other indications.
Navarese et al had found that the reduction of
mortality in STEMI was associated with earlier presentation
and when the patients were treated at high volume PCI
centers (defined as >65 primary PCIs per year. For later
presentation a higher number of procedures (>145/year) is
required to provide a survival benefit.30 Our center therefore
qualified as a high volume PCI center and this may have
factored into the decision of the primary cardiologists to
favour an interventional strategy.
Procedural success for primary PCI in this study was
98.1%, similar to that reported by Jafary et al from the same
center (97.1%) in a 5 year review.27 Similar rates have been
quoted by Farman et al (98.2%) and Shaikh et al (97%), from
public and private sector hospitals in Karachi.31,32
Mortality in our series was comparable to that of the
European registry data 8.1 vs 6.9%, and similar to figures
from India which reported mortality from STEMI to be 8.6%.9
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